Treatment Options After CAR T Therapy for Large B-Cell Lymphoma

Video

The professor of medicine from Duke University School of Medicine discussed treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.

This content originally appeared on our sister site, OncLive.

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
William Chou, MD, on Targeting Progranulin With Gene Therapy for Frontotemporal Dementia
Related Content
Immix and Nexcella Make Progress in US Trial for Light Chain Amyloidosis CAR-T NXC-201

Immix and Nexcella Make Progress in US Trial for Light Chain Amyloidosis CAR-T NXC-201

Noah Stansfield
October 6th 2024
Article

NEXICART-2 has moved on to its expansion cohort after completing dosing of patients in its initial cohort.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – October 4, 2024

CGTLive Staff
October 4th 2024
Article

Review top news and interview highlights from the week ending October 4, 2024.

Data Roundup: September 2024 Features Updates in Ophthalmology Gene Therapy, CAR-T for Lymphoma, and More

Data Roundup: September 2024 Features Updates in Ophthalmology Gene Therapy, CAR-T for Lymphoma, and More

CGTLive Staff
October 4th 2024
Article

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas

First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas

Noah Stansfield
October 3rd 2024
Article

Estrella noted that the patient had been diagnosed with follicular lymphoma grade 3A with high-risk 3B symptoms.

Around the Helix: Cell and Gene Therapy Company Updates – October 2, 2024

Around the Helix: Cell and Gene Therapy Company Updates – October 2, 2024

Noah Stansfield
October 2nd 2024
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Anixa Biosciences Seeks Protocol Change to Enable Repeat Dosing in Trial for Ovarian Cancer CER-T

Anixa Biosciences Seeks Protocol Change to Enable Repeat Dosing in Trial for Ovarian Cancer CER-T

Noah Stansfield
October 2nd 2024
Article

Anixa noted that it had previously obtained clearance of a single-patient investigational new drug application to redose a patient in the trial.

© 2024 MJH Life Sciences

All rights reserved.